News
Irish Medical Firm is awarded FUSION grant
Cork, Ireland- September 10th , 2007: EnBIO Ltd, today announced it was awarded a grant worth in excess €80K via the Intertrade Ireland Fusion programme
FUSION is InterTradeIreland's all-island technology transfer initiative that gives companies access to the wealth of expertise and facilities in universities and colleges across the island of Ireland, allowing them to make strategic advances in innovation and capability.
EnBIO plans to use the programme to hire a biologist who will lead the company’s intensive R&D programme currently underway in the University of Ulster’s Nanotechnology and Integrated BioEngineering Centre.
EnBIO Ltd, develop leading edge surface modication technologies that enables drug eluting properties to metallic surfaces across a multitude of medical sectors.
Commenting on the award Vincent Grady EnBIO Financial Controller said “ The Fusion programme will allow EnBIO expedite the commercialisation of its Frontier™ Technology through co-funding the hiring if a key biologist . The programme will also enable the company future organisation growth plan by financing the completion of management diploma in the Smurfit business school by the newly hired biologist”
EnBIO’s products are based on patent pending surface modification techniques which can be applied to variety of surfaces widely used in medical devices but also in the aeronautical, electronic and food industries.
About EnBIO
EnBIO is an Irish owned company whose proprietary breakthrough technology delivers a step-change in drug eluting capabilities across a multitude of medical device sectors. EnBIO’s area of specialization is in the surface modification of medical devices. Its recent development of novel technology that enables low-cost, room temperature manufacture on bare metal surfaces presents a market-disruptive opportunity Using its proprietary technology EnBIO can apply drug eluting capabilities across a multitude of medical device sectors. The company’s initial focus is the orthopaedic and Cardiac Rhythm Management markets. These technologies will benefit the implant patient by reducing trauma and recovery time following surgical procedure, while enhancing the functionality and long-term viability of the implant itself
About Intertrade
InterTradeIreland, the Trade and Business Development Body, is one of the six cross-border bodies established under the Belfast Agreement, 1999.InterTradeIreland's mission is to enhance the global competitiveness of the all-island economy to the mutual benefit of Ireland and Northern Ireland through measures such as the creation of knowledge-intensive all-island trade and business development networks and the implementation of all-island trade and business development programmes.
site design: